A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection | NEJM

Antibody-mediated rejection is a leading cause of kidney-transplant failure. The targeting of CD38 to inhibit graft injury caused by alloantibodies and natural killer (NK) cells may be a therapeuti...